Adam Friedler - Rami Levi CoCEO Pharm
| RLEVF Stock | USD 74.00 0.00 0.00% |
Insider
Adam Friedler is CoCEO Pharm of Rami Levi Chain
| Phone | 972 7 6888 8600 |
| Web | https://www.rami-levy.co.il |
Rami Levi Management Efficiency
The company has return on total asset (ROA) of 0.0521 % which means that it generated a profit of $0.0521 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3329 %, meaning that it generated $0.3329 on every $100 dollars invested by stockholders. Rami Levi's management efficiency ratios could be used to measure how well Rami Levi manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 14 records | INSIDER Age | ||
| John MBA | Harmony Biosciences Holdings | 57 | |
| David Sachs | Immunitybio | 47 | |
| Helen Luu | Immunitybio | N/A | |
| Jeffrey Aronin | Harmony Biosciences Holdings | 57 | |
| Sandeep MD | Immunitybio | N/A | |
| Jason Rivera | Verra Mobility Corp | N/A | |
| Sharon Goldbach | Harmony Biosciences Holdings | N/A | |
| Hans MD | Immunitybio | 75 | |
| Luis Sanay | Harmony Biosciences Holdings | N/A | |
| David Bradshaw | Harmony Biosciences Holdings | N/A | |
| Stephen JD | Geron | 74 | |
| Norman Blake | Verra Mobility Corp | 50 | |
| Barry MD | Immunitybio | 60 | |
| Leonard MD | Immunitybio | N/A | |
Management Performance
| Return On Equity | 0.33 | |||
| Return On Asset | 0.0521 |
Rami Levi Chain Leadership Team
Elected by the shareholders, the Rami Levi's board of directors comprises two types of representatives: Rami Levi inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Rami. The board's role is to monitor Rami Levi's management team and ensure that shareholders' interests are well served. Rami Levi's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Rami Levi's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Ofir Attias, Dev Centers | ||
| Adina Levy, Deputy Treasurer | ||
| SaydoffBarashi Inbal, Legal Compliance | ||
| Ofer Baharel, Director Management | ||
| Ran Efraty, Head Counsel | ||
| Sandler Ohad, CoCEO Pharm | ||
| Rami Levy, CEO Director | ||
| Adam Friedler, CoCEO Pharm | ||
| Shmulik Levy, Chief Officer | ||
| Yafit Atias, VP Marketing |
Rami Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Rami Levi a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.33 | |||
| Return On Asset | 0.0521 | |||
| Profit Margin | 0.03 % | |||
| Current Valuation | 1.27 B | |||
| Shares Outstanding | 13.78 M | |||
| Shares Owned By Insiders | 40.20 % | |||
| Shares Owned By Institutions | 18.91 % | |||
| Price To Book | 6.90 X | |||
| Price To Sales | 0.58 X | |||
| Revenue | 6.45 B |
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Other Information on Investing in Rami Pink Sheet
Rami Levi financial ratios help investors to determine whether Rami Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Rami with respect to the benefits of owning Rami Levi security.